​

Funding Round

Series A - New Amsterdam Pharma

Series A - New Amsterdam Pharma

Investment Firm

Overview

New Amsterdam is a clinical-stage company focused on the research and development of transformative therapies for cardio-metabolic diseases.

Announced Date

Jan 14, 2021

Closed on Date

Jan 14, 2021

Funding Type

Series A

Highlights

Location

Europe

Social

Investor Lead

Forbion Capital Partners

Forbion Capital Partners

Forbion Capital Partners is a early_stage_venture and post_ipo and seed firm.

Morningside Venture Investments

Morningside Venture Investments

Morningside Venture Investments is a private_equity and venture firm.

Participant Investors

10

Investor Name
Participant InvestorPresight Capital
Participant InvestorPopulation Health Partners
Participant InvestorForbion Capital Partners
Participant InvestorPeter Thiel
Participant InvestorKaiser Permanente

Round Details and Background

New Amsterdam Pharma raised $194412819 on 2021-01-14 in Series A

New Amsterdam is a clinical-stage company focused on the research and development of transformative therapies for cardio-metabolic diseases.

Company Funding History

5

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Jan 01, 2019
Venture Round - New Amsterdam Pharma
1-undefined
Nov 23, 2022
Post-IPO Equity - New Amsterdam Pharma
9-235.0M
Jun 06, 2023
Post-IPO Secondary - New Amsterdam Pharma
-181.6M
Feb 13, 2024
Post-IPO Equity - New Amsterdam Pharma
-175.3M

Recent Activity

There is no recent news or activity for this profile.